Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02NTS
|
|||
| Former ID |
DIB000312
|
|||
| Drug Name |
JNJ-39393406
|
|||
| Synonyms |
JNJ-39393406; UNII-T930SOU82P; T930SOU82P; JNJ 39393406; 953428-73-4; SCHEMBL827762; CHEMBL3545291; DB11867; 1H-1,2,4-Triazole-1-propanamide, 3-((2,2-difluoro-1,3-benzodioxol-5-yl)amino)-N,N-dimethyl-5-(4-pyridinyl)-
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Depression [ICD-11: 6A70-6A7Z; ICD-10: F32.8, F32.9] | Phase 2 | [1] | |
| Tobacco dependence [ICD-11: 6C4A.2; ICD-10: F17.1] | Phase 2 | [1] | ||
| Cognitive impairment [ICD-11: 6D71; ICD-10: F06.7] | Phase 1 | [2] | ||
| Company |
Janssen Pharmaceutica NV
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C19H18F2N6O3
|
|||
| Canonical SMILES |
CN(C)C(=O)CCN1C(=NC(=N1)NC2=CC3=C(C=C2)OC(O3)(F)F)C4=CC=NC=C4
|
|||
| InChI |
1S/C19H18F2N6O3/c1-26(2)16(28)7-10-27-17(12-5-8-22-9-6-12)24-18(25-27)23-13-3-4-14-15(11-13)30-19(20,21)29-14/h3-6,8-9,11H,7,10H2,1-2H3,(H,23,25)
|
|||
| InChIKey |
IURMHZBQEYNQOH-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 953428-73-4
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Neuronal acetylcholine receptor alpha-7 (CHRNA7) | Target Info | Modulator | [3] |
| KEGG Pathway | Calcium signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Cholinergic synapse | ||||
| Nicotine addiction | ||||
| Chemical carcinogenesis | ||||
| Panther Pathway | Alzheimer disease-amyloid secretase pathway | |||
| Nicotinic acetylcholine receptor signaling pathway | ||||
| Reactome | Highly calcium permeable postsynaptic nicotinic acetylcholine receptors | |||
| WikiPathways | SIDS Susceptibility Pathways | |||
| Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | ClinicalTrials.gov (NCT01556217) A Pharmacokinetic Study to Characterize JNJ-39393406 in the Cerebrospinal Fluid of Healthy Volunteers. U.S. National Institutes of Health. | |||
| REF 3 | Allosteric alpha-7 nicotinic receptor modulation and P50 sensory gating in schizophrenia: a proof-of-mechanism study. Neuropharmacology. 2013 Jan;64:197-204. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.